endometriosis and adenomyosis
Conditions
Interventions
1:2.5mg RU-486 po qd *12 months
2:5mg RU-486 po qd*12 months
3:25mg RU-486 po qw*11 months
Sponsors
Women's Hospital, School of Medicine, Zhejiang University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) female, aged >=18, agree to the RU - 486 treatment and signed informed consent; (2) the preoperative vaginal ultrasound and/or nuclear magnetic resonance (MRI) confirmed as a diffuse wall after the front wall of the uterus, and/or glandular myopathy, cause myometrium diffuse thickening obviously; (3) severe dysmenorrhea with menorrhagia; (4) placed separately LNG-IUS invalid or failure, including oral contraceptive drugs; (5) requires the uterus or fertility; (6) 3 months before drug treatment, did not accept other hormonal drug therapy for adenomyosis.
Exclusion criteria
Exclusion criteria: 1. is participating in other clinical trials of patients; 2. the researchers think the other reasons are not suitable for clinical subjects, as follows: (1) the endometrium cervical breast malignant diseases; (2) with serious heart, liver, kidney function disorder; (3) according to the researchers evaluation, the existing patients may as a result of the drug treatment and disease; (4) pregnancy or lactation in the three months before the start of treatment had childbirth, abortion or lactation); (5) going to pregnancy within the established treatment period; (6) body mass index (BMI) > 30 kg/m2; (7) allergic to study drug ingredients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pain;hypermenorrhea;the volumn and length of uterus;endometrial thickness;biochemistry and hormone;life quality score; | — |
Countries
China
Contacts
Public ContactXinmei Zhang
Outcome results
None listed